B

iogen (BIIB) is worth $12 billion more on Friday than it was the night before thanks to some surprising, if nebulous, new data on an in-development treatment for Alzheimer’s disease. The news is undoubtedly positive, but just how positive is a question that has all of biotech puzzling.

Here are the biggest questions about BAN2401, Biogen’s Eisai-partnered Alzheimer’s drug that is either the saving grace for a whole wing of neurology or a red herring of tortured data.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy